Clinical trial · no report yet · Phase 2

NESCIO

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

NCT05148546 ↗
Active, not recruiting
The Netherlands Cancer Institute
Deep

We haven't built an HCP commentary report on NESCIO (nivolumab; nivolumab plus ipilimumab; nivolumab plus relatlimab in resectable clear cell renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Questions raised in the commentary

Automated from the 21 newest of 22 indexed sources (Apr 2022 – Jul 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.

How to identify patients most likely to benefit from perioperative immunotherapy
How neoadjuvant immunotherapy should fit into perioperative treatment
Which endpoints best capture benefit from neoadjuvant immunotherapy

Indexed commentary on NESCIO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	19
Podcasts	2
YouTube	1

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Prospective, Randomized, Neoadjuvant Phase II Study With Combination Immuno-oncology in Primary Clear Cell Renal Cancer at Risk for Recurrence or Distant Metastases (NESCIO-trial)
Phase: Phase 2
Status: Active, not recruiting
Conditions: Renal Cell Carcinoma
Interventions: Neoadjuvant nivolumab; Neoadjuvant ipilimumab; Neoadjuvant relatlimab
Arms: A: Neoadjuvant nivolumab · Experimental
B: Neoadjuvant nivolumab + ipilimumab · Experimental
C: Neoadjuvant nivolumab + relatlimab · Experimental
Enrollment: 69 (estimated)
Primary outcomes: Pathologic response rate
Sponsor: The Netherlands Cancer Institute with Bristol-Myers Squibb
Start: Apr 28, 2022
Primary completion: Apr 22, 2025
Results posted: No
Registry record: NCT05148546 · updated Sep 30, 2025